ArticleScientific reports2026

The metabolic dysfunction-associated steatohepatitis (MASH) drug resmetirom exhibits broad nuclear receptor activity with minimal functional impact.

Annette Kärcher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.